This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NuVasive (NUVA) Launches Modulus ALIF for Anterior Spine Surgery
by Zacks Equity Research
The Modulus ALIF 3D-printed porous titanium implant is the latest addition to NuVasive's (NUVA) AMS portfolio for anterior lumbar interbody fusion procedures.
Medtronic's (MDT) Hugo RAS System Now Available at UC CHRISTUS
by Zacks Equity Research
Recent integration of Medtronic's (MDT) Hugo RAS System at UC CHRISTUS is intended to support the teaching institution's new robotic surgery program.
Quest Diagnostics (DGX) Expands Testing Access With CLX Pact
by Zacks Equity Research
Quest Diagnostics' (DGX) COVID-19 testing will be available through TrustAssure platform for international travelers and live event attendants.
Integra (IART) Releases Favorable PriMatrix Clinical Outcome
by Zacks Equity Research
Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.
Thermo Fisher (TMO) Advances Customer Research With New Launch
by Zacks Equity Research
Thermo Fisher's (TMO) new instrument enables high-resolution images of nanoparticles and beam-sensitive materials to be obtained from a commercially available desktop SEM.
Thermo Fisher (TMO) to Meet Plasmid DNA Demand With New Facility
by Zacks Equity Research
Thermo Fisher's (TMO) new facility will manufacture materials that are essential for production of plasmid-based therapies and vaccines.
Is BellRing Brands (BRBR) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Integra's (IART) SurgiMend Gets Innovative Technology Contract
by Zacks Equity Research
Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.
Thermo Fisher's (TMO) New Pact Drives Sustainable Lab Practices
by Zacks Equity Research
Thermo Fisher (TMO) expects to ACT label more than 1,200 additional SKUs to allow research, pharmaceutical and clinical laboratories to achieve their sustainability objectives.
Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) on robust international growth and raised 2021 outlook.
Thermo Fisher's (TMO) Rapid DNA Solution Gets FBI Approval
by Zacks Equity Research
Thermo Fisher's (TMO) RapidHIT ID DNA Booking System allows seamless integration of Rapid DNA into the law enforcement booking agency process.
Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by strong diagnostic arm growth and improvement in base business.
Walgreens (WBA), VillageMD State 2021 Primary Healthcare Goal
by Zacks Equity Research
With this Walgreens (WBA) and VillageMD are on track to achieve their January 2021 goal of opening at least 600 Village Medical primary care practices in more than 30 U.S. markets over the next four years.
QIAGEN's (QGEN) NeuMoDx HAdV Quant Assay Wins CE-IVD Mark
by Zacks Equity Research
QIAGEN's (QGEN) NeuMoDx solutions at present offer CE-IVD tests for various viral and bacterial pathogens.
Amedisys' (AMED) VNA Assets Buyout Boosts Home Health-Hospice
by Zacks Equity Research
Leveraging on VNA's home health and hospice care legacy, Amedisys (AMED) expects to provide additional scale and resources.
Thermo Fisher (TMO) Introduces CoE in Clinical Metabolomics
by Zacks Equity Research
Thermo Fisher's (TMO) new research collaboration is aimed to provide the metabolomics community with advanced, best practices and standard operating procedures.
IDEXX Laboratories (IDXX) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Strong sales at the CAG and LPD arms are driving the top line for IDEXX Laboratories (IDXX).
Here's Why You Should Add STERIS (STE) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to strong segmental performance and bullish 2022 outlook.
QIAGEN (QGEN) Faces COVID-Support Sales Drop, Huge Debt
by Zacks Equity Research
With gradually falling COVID-19 cases, since the beginning of 2021, QIAGEN's (QGEN) COVID-19 testing related product lines are seeing significant decline in sales.
NVIDIA, Lumentum, Maravai LifeSciences, Baxter International and BellRing Brands highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
NVIDIA, Lumentum, Maravai LifeSciences, Baxter International and BellRing Brands highlighted as Zacks Bull and Bear of the Day
Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market
by Riya Anand
Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.
Abbott's (ABT) DAPT for High Bleeding Risk Gets FDA Approval
by Zacks Equity Research
Abbott's (ABT) DAPT can be discontinued safely early as short as 28 days with no higher risk in patient adverse events.
Child Health in Focus in Face of Delta Strain Threat: 3 Picks
by Urmimala Biswas
Here are three stocks, BAX, BRBR, and MRVI with a favorable Zacks Rank and huge prospects in child healthcare at present.
QIAGEN (QGEN) & Verogen Team Up to Employ NGS-Based Forensics
by Zacks Equity Research
QIAGEN's (QGEN) new collaboration will offer customers advanced tools and comprehensive support for HID workflows in laboratories.
Globus Medical (GMED) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) owing to significant trend improvement and the company's focus on product development.